Biotechnology and Pharmaceutical Market Forecasts from BCC Research

BCC Research report's cover the latest pharmaceutical market research and provide in-depth market analysis, forecasts, trends, patent analysis, and profiles of major players within the markets. BCC Research biotechnology reports cover all the key areas in biotechnology from healthcare, telemedicine, food and beverage, biopharmaceuticals, and agricultural technologies.  BCC has recently released several reports in these categories as well as upcoming reports that are due to publish.

Explore these recently published reports:

Biologic Therapeutic Drugs: Technologies and Global Markets - BIO079B:

This study provides a comprehensive analysis of biologics, or biopharmaceuticals, on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends (through 2017), in order to quantify and qualify the market for therapeutic drug products in the biologics segment.

MEMS Devices in Global Medical Markets - HLC129A:

This study measures, forecasts and segments microelectromechanical system (MEMS) devices in the medical market based on products and applications. It includes market estimates for a forecast period of 2012 through 2017.

Global Markets for Drug-Device Combinations - PHM045C:

This report analyzes the market for drug-device combination products. It provides descriptions of technologies and products, a review of the status of research and development (R&D) initiatives and a forecast of market revenues through 2017. Company profiles, clinical trials, and a patent analysis are provided as well.

Single-Use Technologies for Biopharmaceuticals: Global Markets - BIO099A:

The objective of the report is to provide an intensive assessment of the market for single-use technologies specifically used in biopharmaceutical production. Includes forecasts through 2017.

The Global Market for Pain Management Drugs and Devices - HLC026D:

This BCC Research report, The Global Market for Pain Management Drugs and Devices, provides an overview of products included in this market, and detailed analyses of markets and competitive environments. The study includes information about significant products, players, issues and trends, regulatory issues, and other information affecting the pain management industry.

Therapies and Biomarkers for Inflammatory Bowel Disease - PHM125A:

This BCC Research report, Therapies and Biomarkers for Inflammatory Bowel Disease, provides a detailed analysis of the products and technologies that define the market space and summarizes the composition and dynamics of individual companies in the competitive environment. The study also includes an overview of the relevant regulatory issues, patent landscapes and strategic partnerships that will play substantial roles in shaping the market in the future.

Drugs and Diagnostics for Hematological Disorders: Global Markets - PHM116A:

The scope of This BCC Research report, Drugs and Diagnostics for Hematological Disorders: Global Markets, is testing, screening technology and also therapeutics markets for hematological disorders and blood cancers. The report also includes the regulatory environment, current technologies, new technologies, hematological disorders and cancer incidence, market projections and market share, along with latest trends and new developments.

Contact a business development representative now to discuss these upcoming titles:

•    Immunoassays: Technologies and Global Markets - BIO033B
•    Global Markets and Technologies for Optical Coherence Tomography (OCT) - HLC097A
•    Global Markets and Technologies for Pandemic Control - PHM042B
•    Molecular Diagnostics: Technologies and Global Markets - BIO063B
•    Infusion Devices: Technologies and Global Markets - HLC071B

Therapies and Biomarkers for Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is made up of two related disorders – Crohn’s disease and ulcerative colitis – in which the intestinal tract experiences severe and chronic inflammation.  No cure currently exists for the disease;  thus, the primary goal of disease management is to minimize complications and unnecessary suffering. As a disease class, IBD is distinct from irritable bowel syndrome (IBS), although the two share some symptoms. IBD causes irreversible damage to the bowel and healthcare utilization. Disease-associated morbidity is significant for those with progressive and difficult-to-manage disease.
Crohn’s disease and ulcerative colitis have distinct pathological and clinical characteristics, and despite decades of research into their origins, disease pathogenesis for both conditions remains poorly understood.

Crohn’s Disease

Crohn’s disease is characterized by transmural inflammation (i.e., inflammation that extends through the entire wall of the digestive tract), as well as by skip lesions (i.e., sections of inflamed tissue separated by noninflamed tissue). The transmural inflammatory nature of Crohn’s disease often leads to fibrosis and to obstructive clinical presentations that are not typically seen in ulcerative colitis. 
Transmural inflammation also can result in gut microperforations and the formation of fistulae (i.e., a permanent abnormal passageway between two organs in the body or between an organ and the exterior of the body).

Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory condition characterized by relapsing and remitting episodes of inflammation limited to the mucosal layer of the colon.  It almost always involves the rectum and, in some cases, it may extend to involve other portions of the colon in a continuous manner (i.e., inflamed tissue forms a continuous patch of disease tissue).

The peak age of onset for IBD is between 20 and 30, although it may occur at any age.  Approximately 10% of cases occur in individuals younger than 18.  Ulcerative colitis is slightly more common in males, whereas Crohn’s disease is marginally more frequent in females. IBD occurs more in people of Caucasian and Ashkenazic Jewish origin than in other racial and ethnic subgroups.

Hyperactive inflammation is a hallmark of IBD, and several therapeutic strategies for controlling inflammation are part of its current treatment plan.  Aminosalicylates, corticosteroids, immunosuppressants, and biologic therapies all are used to control the inflammation associated with IBD.

The mechanisms through which these compounds suppress inflammation may be different, but the ultimate goal of pharmacotherapy for IBD is to suppress the abnormal activation of the immune system to allow for the body’s natural repair mechanisms to operate and fix the damaged intestinal tract.

The above is an extract from the BCC Research report, Therapies and Biomarkers for Inflammatory Bowel Disease (PHM125A). To download the complimentary first chapter, please click above.